Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...

People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...

The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...